peoplePerson
Fei Ma
A breast oncologist who led Chinese pyrotinib and ADC trials and studies of ctDNA in HER2-positive disease.
Fei Ma has led trials of pyrotinib and HER2-directed antibody-drug conjugates in Chinese patients and research on circulating tumour DNA and resistance in HER2-positive breast cancer.
Role
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Specialisms
Breast cancerHER2Antibody-drug conjugatesCirculating tumour DNA
Pages like this
not linked directly; found by shared links- TrialHORIZON-Breast01
Shares Pyrotinib, HER2-positive breast cancer.
- PersonBinghe Xu
Shares Pyrotinib, Cancer Hospital, Chinese Academy of Medical Sciences, HER2, HER2-positive breast cancer.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares Pyrotinib, HER2-positive breast cancer.
- ProductTrastuzumab duocarmazine
Shares HER2, HER2-positive breast cancer.
- PersonJoaquín Arribas
Shares HER2, HER2-positive breast cancer.
- PersonNancy U. Lin
Shares HER2, HER2-positive breast cancer.
- ProductTrastuzumab brengitecan
Shares HER2, HER2-positive breast cancer.
- ProductNeratinib
Shares HER2, HER2-positive breast cancer.